At 24 months' follow-up, the only phase 3 randomized clinical trial to directly compare functional and oncologic outcomes between robot-assisted laparoscopic prostatectomy and open radical retropubic ...

Prostate cancer is the most common malignant tumor in men, accounting for 29% of male neoplasm diagnoses in the United States alone. Radical prostatectomy remains the preferred treatment for localized ...

In this study, researchers aimed to determine whether adding apalutamide to ADT improves outcomes in high-risk prostate cancer compared to placebo plus ADT.

With Men’s Health Week approaching, it is a good time to encourage open discussions about various health conditions, particularly prostate health. Driven by embarrassment, misconceptions, and a lack ...

With long-term follow-up, mpMRI-guided salvage radiotherapy achieved excellent durable local control. The absence of in-field ...

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We conducted a ...

Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP) ...

Here is how robotic surgeries are paving way for new gen cancer treatment in the country - Read on to know all about it.

Radical prostatectomy does not ensure a cure, with one in three men experiencing cancer recurrence and elevated PSA levels within 10 years post-surgery. Significant side effects of prostate removal ...